A US FDA advisory committee on March 27 recommended approval of US WorldMeds LLC's opioid withdrawal drug Lucemyra (lofexidine) but for a narrower indication than requested and for the lower of two doses studied in the Phase III trials.
If FDA follows the recommendations of the majority of its external advisors, lofexidine would be labeled for the mitigation of...





